Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer

Simple Summary Nowadays, in clinics, there is a lack of reliable biomarkers that could serve as tools allowing for early cancer detection, prediction of therapy response, tumor recurrence, and TNBC course. In this review, we summarized the most recent findings on the applicability of unique blood circulating ncRNAs for management of TNBC. This review was supplemented by bioinformatics analysis for better understanding of molecular processes in which ncRNAs are involved, to promote individual TNBC phenotype and tumor action. Triple negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, and is related to unfavorable prognosis and limited treatment strategies. Currently, there is a lack of reliable biomarkers allowing for the clinical management of TNBC. This is probably caused by a complex molecular background, leading to the development and establishment of a unique tumor phenotype. Recent studies have reported non-coding RNAs (ncRNAs) not only as the most promising class of molecular agents with a high applicability to manage human cancers, including TNBC, but also as robust and non-invasive biomarkers that are able to be monitored in blood circulation, with the application of liquid biopsy. There is a lack of papers discussing the role of blood-circulating ncRNAs as diagnostic, predictive, and prognostic biomarkers for TNBC. In this paper, we summarized the available literature reports on the utility of blood-circulating ncRNAs for TNBC management. Additionally, we supplemented this review by bioinformatics analysis, for better understanding of the role of ncRNAs' machinery in the development of a unique TNBC phenotype.